Supplementary Figure S3 from Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways

Mario E. Lacouture; Elena Goleva; Neil J. Shah; Veronica Rotemberg; Lukas Kraehenbuehl; Kwami F. Ketosugbo; Taha Merghoub; Tara Maier; Alexander Bang; Stephanie Gu; Trina Salvador; Andrea P. Moy; Taras Lyubchenko; Olivia Xiao; Clifton F. Hall; Evgeny Berdyshev; James Crooks; Ryan Weight; Jeffrey A. Kern; Donald Y.M. Leung

doi:10.1158/1078-0432.26134210.v1

Abstract

Supplementary Figure S3. Serum IgE levels in patients with cancer experiencing checkpoint inhibitor induced immune-related cutaneous adverse events (ircAE).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lacouture et al. (2024) studied this question.

synapsesocial.com/papers/68e62195b6db6435875b376f https://doi.org/10.1158/1078-0432.26134210.v1

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure S3 from Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways

Abstract

Discussion

Cite This Study

Supplementary Figure S3 from Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways

Abstract

Discussion

Cite This Study

Keep reading

Keep reading